Drug Profile
Fibrinogen - Liminal BioSciences
Latest Information Update: 14 Sep 2023
Price :
$50
*
At a glance
- Originator ProMetic Life Sciences
- Developer Liminal BioSciences
- Class Acute-phase proteins; Antihaemorrhagics; Blood coagulation factors; Coagulants
- Mechanism of Action Fibrinogen replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Afibrinogenaemia
Most Recent Events
- 14 Sep 2023 Discontinued - Preclinical for Afibrinogenaemia in Canada (Parenteral) (Liminal BioSciences pipeline, September 2023)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Afibrinogenaemia in Canada (Parenteral)
- 03 Oct 2019 Prometic Life Sciences is now called Liminal BioSciences